cIAP1 Ligand-Linker Conjugates 12 belong to the category of E3 Ligase Ligand-Linker Conjugates, specifically designed for research in PROTAC (Proteolysis Targeting Chimera) drug development. These specialized molecules consist of a high-affinity ligand for the cellular inhibitor of apoptosis protein 1 (cIAP1) strategically connected to a functional linker. As a key component in the construction of PROTACs, the cIAP1 Ligand-Linker Conjugate 12 enables the recruitment of cIAP1 E3 ubiquitin ligase to target proteins, promoting their ubiquitination and subsequent degradation by the proteasome. Ideal for scientists focused on targeted protein degradation, these conjugates offer a flexible platform for linking to protein-of-interest (POI) ligands, facilitating the design and synthesis of novel PROTAC molecules. Harness the power of cIAP1-mediated protein degradation to advance cancer research, neurodegenerative disease studies, and the exploration of new therapeutic targets. With optimized linker chemistry, cIAP1 Ligand-Linker Conjugates 12 provide reliable and consistent performance for your custom PROTAC development needs.
Structure of 2095244-52-1
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C46H64N4O12S2
Molecular Weight
929.15
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
cIAP1 Ligand-Linker Conjugates 12 are specialized chemical tools designed for targeted protein degradation applications. As essential building blocks in the development of PROTACs (Proteolysis Targeting Chimeras), these conjugates leverage the unique properties of the cellular inhibitor of apoptosis protein 1 (cIAP1), a key E3 ubiquitin ligase, to facilitate selective protein ubiquitination. Employing a ligand that specifically binds to cIAP1, connected via a chemical linker, this product is integral for constructing heterobifunctional molecules targeting proteins of interest for degradation.
Mechanism
The mechanism of cIAP1 Ligand-Linker Conjugates 12 centers on harnessing the ubiquitin-proteasome system for targeted protein degradation. These conjugates feature a cIAP1-binding ligand tethered to a functional linker, which can be chemically connected to a ligand that recognizes a specific target protein. When incorporated into a PROTAC molecule, the conjugate functions by simultaneously binding cIAP1 and the target protein, bringing them into close proximity. This induced proximity enables cIAP1 to ubiquitinate the target protein, marking it for recognition and rapid degradation by the cellular proteasome machinery. This approach allows for selective and catalytic elimination of disease-relevant proteins within cells.
Applications
cIAP1 Ligand-Linker Conjugates 12 are versatile and powerful components for next-generation drug discovery and protein degradation research. Their principal applications include: (1) serving as a core element in PROTAC molecule design to induce targeted degradation of disease-associated proteins, (2) enabling the functional study of previously undruggable proteins in cellular systems, and (3) advancing therapeutic strategies for oncology, neurodegeneration, and other conditions where aberrant protein accumulation is implicated. These conjugates are also valuable for validating E3 ligase compatibility and linker optimization in rational PROTAC development.
• Selective cIAP1 ligand ensures targeted protein degradation, enhancing therapeutic specificity in PROTAC applications.
• Pre-installed linker simplifies PROTAC assembly, accelerating drug discovery workflows and reducing synthesis time.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
CAS No.: 2095244-52-1
